These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31791720)

  • 1. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review.
    Kuszmaul AK; Palmer EC; Frederick EK
    J Am Pharm Assoc (2003); 2020; 60(1):145-152. PubMed ID: 31791720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lofexidine, an {alpha}2-receptor agonist for opioid detoxification.
    Gish EC; Miller JL; Honey BL; Johnson PN
    Ann Pharmacother; 2010 Feb; 44(2):343-51. PubMed ID: 20040696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine for managing opioid withdrawal.
    Gowing L; Ali R; White JM; Mbewe D
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal.
    Gorodetzky CW; Walsh SL; Martin PR; Saxon AJ; Gullo KL; Biswas K
    Drug Alcohol Depend; 2017 Jul; 176():79-88. PubMed ID: 28527421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.
    Doughty B; Morgenson D; Brooks T
    Ann Pharmacother; 2019 Jul; 53(7):746-753. PubMed ID: 30724094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid antagonists with minimal sedation for opioid withdrawal.
    Gowing L; Ali R; White JM
    Cochrane Database Syst Rev; 2017 May; 5(5):CD002021. PubMed ID: 28553701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial.
    Fishman M; Tirado C; Alam D; Gullo K; Clinch T; Gorodetzky CW;
    J Addict Med; 2019; 13(3):169-176. PubMed ID: 30531234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
    Yu E; Miotto K; Akerele E; Montgomery A; Elkashef A; Walsh R; Montoya I; Fischman MW; Collins J; McSherry F; Boardman K; Davies DK; O'Brien CP; Ling W; Kleber H; Herman BH
    Drug Alcohol Depend; 2008 Sep; 97(1-2):158-68. PubMed ID: 18508207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White JM
    Cochrane Database Syst Rev; 2009 Jul; (3):CD002025. PubMed ID: 19588330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha₂-adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White JM
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD002024. PubMed ID: 27140827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha2-adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell MF; Ali R; White JM
    Cochrane Database Syst Rev; 2014 Mar; (3):CD002024. PubMed ID: 24683051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore.
    Guo S; Manning V; Yang Y; Koh PK; Chan E; de Souza NN; Assam PN; Sultana R; Wijesinghe R; Pangjaya J; Kandasami G; Cheok C; Lee KM; Wong KE
    J Subst Abuse Treat; 2018 Aug; 91():1-11. PubMed ID: 29910009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials.
    Strang J; Bearn J; Gossop M
    Am J Addict; 1999; 8(4):337-48. PubMed ID: 10598217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
    Walsh SL; Strain EC; Bigelow GE
    Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha2-adrenergic agonists in opioid withdrawal.
    Gowing LR; Farrell M; Ali RL; White JM
    Addiction; 2002 Jan; 97(1):49-58. PubMed ID: 11895270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha2-adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White JM
    Cochrane Database Syst Rev; 2009 Apr; (2):CD002024. PubMed ID: 19370574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha2 adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002024. PubMed ID: 15495025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal.
    Lin SK; Strang J; Su LW; Tsai CJ; Hu WH
    Drug Alcohol Depend; 1997 Nov; 48(2):127-33. PubMed ID: 9363412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha2 adrenergic agonists for the management of opioid withdrawal.
    Gowing L; Farrell M; Ali R; White J
    Cochrane Database Syst Rev; 2003; (2):CD002024. PubMed ID: 12804419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital.
    Kahn A; Mumford JP; Rogers GA; Beckford H
    Drug Alcohol Depend; 1997 Jan; 44(1):57-61. PubMed ID: 9031821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.